Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06527222

A Study of Ranolazine in ALS

Led by Swathy Chandrashekhar, MBBS · Updated on 2025-10-28

72

Participants Needed

7

Research Sites

52 weeks

Total Duration

On this page

Sponsors

S

Swathy Chandrashekhar, MBBS

Lead Sponsor

A

ALS Association

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

CONDITIONS

Official Title

A Study of Ranolazine in ALS

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years or older
  • Diagnosed with clinically definite, possible, probable, or lab-supported probable ALS per revised El Escorial criteria
  • Forced vital capacity (FVC) greater than or equal to 50%
  • Able to swallow pills at the start of the study and expected to continue for the study duration
  • If taking ALS modifying medications, on a stable dose for at least 30 days
  • Experiencing 4 or more muscle cramps per week during a 2-week screening period
Not Eligible

You will not qualify if you...

  • Disease duration less than 5 years
  • Using tracheostomy invasive ventilation or noninvasive ventilation more than 12 hours/day
  • Pregnant or lactating women, adults unable to consent, and prisoners
  • Taking ranolazine or any investigational drug within 30 days or 5 half-lives before screening
  • Medically uncontrolled heart, liver, or kidney disease
  • Baseline QTc interval prolongation over 450 ms for men or 470 ms for women, history of long QT syndrome, or use of medications that prolong QT interval
  • Participation in another experimental drug trial within 30 days before screening
  • Not on a stable dose of medications for muscle cramps for at least 30 days or have not been off these medications for at least 30 days prior to randomization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

2

Mayo Clinic Florida

Jacksonville, Florida, United States, 32224

Actively Recruiting

3

University of Kansas Medical Center

Fairway, Kansas, United States, 66205

Actively Recruiting

4

University of Kansas Medical Center: Wichita

Wichita, Kansas, United States, 67214

Actively Recruiting

5

University of Missouri Health Care

Columbia, Missouri, United States, 65212

Actively Recruiting

6

The Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

7

National Neuromuscular Research Institute, PLLC.

Austin, Texas, United States, 78759

Not Yet Recruiting

Loading map...

Research Team

K

Katie Lillig, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Ranolazine in ALS | DecenTrialz